Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)-Reference-Cited by-同舟云学术

Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)

Published:2017-12-19 Issue:6 Volume:124 Page:1216-1224
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Pal Sumanta Kumar¹,Patel Jaymala²,He Miaoling¹,Foulk Brad²,Kraft Katherine²,Smirnov Denis A.²,Twardowski Przemyslaw¹,Kortylewski Marcin³,Bhargava Vipul²,Jones Jeremy O.¹

Affiliation:

1. Department of Medical Oncology and Therapeutics Research; City of Hope Comprehensive Cancer Center; Duarte California

2. Janssen Pharmaceuticals; Spring House Pennsylvania

3. Department of Cancer Immunotherapeutics and Tumor Immunology; City of Hope Comprehensive Cancer Center; Duarte California

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference30 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate;Huggins;Cancer Res,1941

3. Studies on Prostate Cancer: II. The effects of castration on advanced carcinoma of the prostate gland;Huggins;JAMA Surgery,1941

4. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer;Aragon-Ching;Front Biosci,2007

5. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma;Eisenberger;J Clin Oncol,1986

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer;British Journal of Cancer;2023-08-03

2. Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer;Cancer Letters;2023-07

3. Neurokinin-1 receptor drives PKCɑ-AURKA/N-Myc signaling to facilitate the neuroendocrine progression of prostate cancer;Cell Death & Disease;2023-06-29

4. Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening;Scientific Reports;2023-06-03

5. Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer;Expert Review of Anticancer Therapy;2023-04-28